Targeting of Hematologic Malignancies with PTC299, A Novel Potent Inhibitor of Dihydroorotate Dehydrogenase with Favorable Pharmaceutical Properties

PTC299 was identified as an inhibitor of VEGFA mRNA translation in a phenotypic screen and evaluated in the clinic for treatment of solid tumors. To guide precision cancer treatment, we performed extensive biological characterization of the activity of PTC299 and demonstrated that inhibition of VEGF...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Mol Cancer Ther
Egile Nagusiak: Cao*, Liangxian, Weetall, Marla, Trotta, Christopher, Cintron, Katherine, Ma, Jiyuan, Kim, Min Jung, Furia, Bansri, Romfo, Charles, Graci, Jason D., Li, Wencheng, Du, Joshua, Sheedy, Josephine, Hedrick, Jean, Risher, Nicole, Yeh, Shirley, Qi, Hongyan, Arasu, Tamil, Hwang, Seongwoo, Lennox, William, Kong, Ronald, Petruska, Janet, Moon, Young-Choon, Babiak, John, Davis, Thomas W., Jacobson, Allan, Almstead, Neil G., Branstrom, Art, Colacino, Joseph M., Peltz, Stuart W.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2018
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6318026/
https://ncbi.nlm.nih.gov/pubmed/30352802
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-18-0863
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak